<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402271</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-55092</org_study_id>
    <secondary_id>EU-21119</secondary_id>
    <secondary_id>2010-024077-39</secondary_id>
    <nct_id>NCT01402271</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer</brief_title>
  <official_title>Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of&#xD;
      pazopanib hydrochloride when given together with paclitaxel and carboplatin in treating&#xD;
      patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or&#xD;
      peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum-tolerated dose of pazopanib hydrochloride in combination with&#xD;
           paclitaxel and carboplatin in patients with platinum-refractory or -resistant ovarian&#xD;
           epithelial, fallopian tube, or peritoneal carcinoma. (Phase I)&#xD;
&#xD;
        -  To determine the progression-free survival (PFS) at 1 year according to the RECIST 1.1&#xD;
           in these patients. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the safety and adverse event profiles in these patients. (Phase I and phase&#xD;
           II)&#xD;
&#xD;
        -  To determine the pharmacokinetics (PK) of this regimen using intensive sampling. (Phase&#xD;
           I)&#xD;
&#xD;
        -  To determine if there is PK interaction (and if so, what kind of PK interaction) between&#xD;
           carboplatin and paclitaxel as well as pazopanib hydrochloride. (Phase I)&#xD;
&#xD;
        -  To determine the response rate (RR) in these patients. (Phase I)&#xD;
&#xD;
        -  To determine and evaluate predictive biomarkers. (Phase I and phase II)&#xD;
&#xD;
        -  To determine the RR, overall survival (OS), and PFS of these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study of carboplatin, paclitaxel,&#xD;
      and pazopanib hydrochloride followed by a phase II randomized study.&#xD;
&#xD;
        -  Phase I: Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 30&#xD;
           minutes on day 1. Patients also receive oral pazopanib hydrochloride* once daily on days&#xD;
           2-7. Treatment repeats every week for up to 18 courses**. Patients then continue to&#xD;
           receive oral pazopanib hydrochloride once daily in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Pazopanib hydrochloride is started in course 2 in order to evaluate the&#xD;
      pharmacokinetic of paclitaxel and carboplatin prior to pazopanib hydrochloride&#xD;
      administration.&#xD;
&#xD;
        -  Phase II: Patients are stratified according to center, disease status&#xD;
           (platinum-refractory vs -resistant) and number of prior lines of treatment (1 vs more&#xD;
           than 1). Patients are randomized in a 2:1 ratio (arm II [experimental arm]: arm I&#xD;
           [standard arm]) to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I (standard arm): Patients receive paclitaxel IV over 1 hour and carboplatin IV&#xD;
                over 30 minutes on day 1. Treatment repeats every week for up to 18 courses.&#xD;
&#xD;
             -  Arm II (experimental arm): Patients receive paclitaxel IV over 1 hour and&#xD;
                carboplatin IV over 30 minutes on day 1. Patients also receive oral pazopanib&#xD;
                hydrochloride once daily on days 2-7. Treatment repeats every week for up to 18&#xD;
                courses**. Patients then continue to receive oral pazopanib hydrochloride once&#xD;
                daily in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: **After course 9, chemotherapy will be interrupted for 1 week.&#xD;
&#xD;
      Blood samples are collected from some patients periodically for pharmacokinetic and biomarker&#xD;
      studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3 weeks, every 3 months for&#xD;
      2 years, and then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of pazopanib hydrochloride, carboplatin, and paclitaxel (phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival according to RECIST 1.1 at 1 year (phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of pazopanib, carboplatin, and paclitaxel (phase I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability according to CTCAE 4.0 (phase I and phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (phase I and phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers (phase I and phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age-related subanalysis for toxicity and efficacy (cut-off 65 years old) (phase II)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel and carboplatin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Paclitaxel and carboplatin only</arm_group_label>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel and carboplatin only</arm_group_label>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib hydrochloride</intervention_name>
    <arm_group_label>Paclitaxel and carboplatin only</arm_group_label>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>pazopanib in combination with paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal carcinoma&#xD;
&#xD;
               -  Recurrent disease&#xD;
&#xD;
          -  Received at least 1 prior platinum treatment and developed platinum-refractory disease&#xD;
             (i.e., progression within 4 weeks of platinum administration) or platinum-resistant&#xD;
             disease (i.e., progression within 6 months after the last platinum dose)&#xD;
&#xD;
               -  There is no restriction on the number of prior lines of treatment&#xD;
&#xD;
               -  Non-platinum treatment is allowed after proven platinum-resistance or -refractory&#xD;
                  disease&#xD;
&#xD;
          -  Evaluable (measurable or nonmeasurable) disease according to RECIST version 1.1&#xD;
             criteria&#xD;
&#xD;
          -  Patients with refractory disease on weekly paclitaxel and carboplatin regimen are&#xD;
             excluded (phase II only)&#xD;
&#xD;
          -  No known gastrointestinal intraluminal metastatic lesions with risk of bleeding&#xD;
&#xD;
          -  No known endobronchial lesions and/or lesions infiltrating major pulmonary vessels&#xD;
&#xD;
          -  No known brain metastases or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  PT, aPTT, or INR ≤ 1.2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN*&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN*&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Urine protein creatinine ratio &lt; 1 OR 24-hour urine protein &lt; 1 g&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during study therapy&#xD;
&#xD;
          -  No other prior primary or recurrent malignancies treated within the past 2 years&#xD;
             except for completely resected non-melanomatous skin carcinoma or successfully treated&#xD;
             carcinoma in situ of the skin or uterine cervix&#xD;
&#xD;
          -  No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             similar or related to paclitaxel, carboplatin, and pazopanib hydrochloride&#xD;
&#xD;
          -  Able to receive infusions of paclitaxel and carboplatin&#xD;
&#xD;
          -  Able to swallow pazopanib hydrochloride tablets&#xD;
&#xD;
          -  No unstable or serious condition (e.g., uncontrolled infection requiring systemic&#xD;
             therapy)&#xD;
&#xD;
          -  No history of any of the following cardiovascular conditions within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  NYHA class III-IV congestive heart failure&#xD;
&#xD;
          -  LVEF &gt; 50% as assessed by ultrasound or MUGA scan, if clinically indicated&#xD;
&#xD;
          -  No inadequately controlled hypertension (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg)&#xD;
&#xD;
               -  Initiation or adjustment of blood pressure medication is permitted prior to the&#xD;
                  study entry&#xD;
&#xD;
          -  No prolonged corrected QT interval (QTc) defined as &gt; 480 msecs using Bazett formula&#xD;
&#xD;
          -  No history of cerebrovascular accident within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
               -  Untreated deep venous thrombosis (DVT)&#xD;
&#xD;
                    -  Patients with recent DVT who have been treated with therapeutic&#xD;
                       anti-coagulating agents for at least 6 weeks are eligible&#xD;
&#xD;
          -  No evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  No clinically significant gastrointestinal (GI) tract abnormalities that may increase&#xD;
             the risk for GI bleeding including, but not limited to, any of the following:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g., ulcerative colitis or Crohn disease)&#xD;
&#xD;
          -  No history of bowel obstruction (excluding postoperative (i.e. within 4 weeks post&#xD;
             surgery)) during the whole prior history of the patient, or other GI condition with&#xD;
             increased risk of perforation such as clear infiltration into the rectosigmoid, colon&#xD;
             or small bowel.&#xD;
&#xD;
          -  No clinically significant GI abnormalities that may affect absorption of&#xD;
             investigational product including, but not limited to, any of the following:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of stomach or small bowel&#xD;
&#xD;
          -  No hemoptysis in excess of 2.5 mL (one-half teaspoon) within 8 weeks prior to first&#xD;
             dose of study drug&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No trauma within the past 28 days&#xD;
&#xD;
          -  No prior non-healing wounds, fracture, or ulcer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No ongoing toxicity from prior anticancer therapy &gt; grade 1 and/or that is progressing&#xD;
             in severity, except for alopecia and ≤ grade 2 peripheral neuropathy&#xD;
&#xD;
          -  No cardiac angioplasty or stenting within the past 6 months&#xD;
&#xD;
          -  No coronary artery bypass graft surgery within the past 6 months&#xD;
&#xD;
          -  At least 14 days since prior radiotherapy, surgery, or tumor embolization ,&#xD;
             chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal&#xD;
             therapy (28 days for drugs with a longer half-life)&#xD;
&#xD;
          -  At least 14 days since prior (28 days for drugs with a longer half-life) and no&#xD;
             concurrent prohibited medications&#xD;
&#xD;
          -  At least 28 days since prior major surgery (procedures such as catheter placement and&#xD;
             diagnostic endoscopic procedures are not considered to be major)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignace B. Vergote, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Boere, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Casado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional De La Citadelle</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 23, 2011</study_first_submitted>
  <study_first_submitted_qc>July 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

